Elud­ed by clear suc­cess in esophageal car­ci­no­ma, Mer­ck touts sub­group OS win for Keytru­da

Mer­ck didn’t ex­act­ly get the clean sweep it want­ed to show Keytru­da beats out stan­dard sec­ond-line ther­a­py in esophageal or esoph­a­gogas­tric junc­tion car­ci­no­ma — but the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.